Affiliation:
1. Nuclear Engineering Department Science and Research Branch, Islamic Azad University, Tehran, Iran
2. Agricultural, Medical & Industrial Research School, Nuclear Science and Technology Research Institute, P.O. Box: 31485/498, Karaj, Iran
Abstract
Abstract
For roughly 25 years, 125I sources have been used in the treatment of various malignant diseases such as prostate cancer. Three new brachytherapy sources, IR01-125I, IR02-125I and IR03-125I, have been developed and are designed for permanent implant application. The Monte Carlo radiation transport code version MCNP 5 was used to calculate the dosimetry parameters around the sources in accordance with the updated report of the American Association of Physicists in Medicine (AAPM), Task Group No. 43. For each source, the dose rate constant Λ, the radial dose function gL(r), and the anisotropy function F(r, θ), were obtained. The results indicated a dose rate constant of 0.932 ± 0.01, 0.934 ± 0.01 and 0.939 ± 0.01 Gy h−1 U−1 for the IR01-125I, IR02-125I and IR03-125I sources respectively. With the goal of determining an optimal design for a 125I source, each seed's parameters were compared with other seeds. In this study, the optimal source IR03-125I provides the most isotropic dose distribution in water. Finally, the results for optimal source were compared with published results for those of other commercial sources.
Subject
Safety, Risk, Reliability and Quality,General Materials Science,Nuclear Energy and Engineering,Nuclear and High Energy Physics,Radiation
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献